145 related articles for article (PubMed ID: 16807458)
1. Topoisomerase I, II alpha and II beta mRNA expression in peripheral blood mononuclear cells of patients with solid tumor: preliminary results.
Cartei G; Trestin A; Colombrino E; Nadai M; Richter SN; Barzon L; Palù G; Palumbo M;
Ann Oncol; 2006 May; 17 Suppl 5():v25-28. PubMed ID: 16807458
[TBL] [Abstract][Full Text] [Related]
2. In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer.
Richter SN; Cartei G; Nadai M; Trestin A; Barzon L; Palumbo M; Palù G
Ann Oncol; 2006 May; 17 Suppl 5():v20-24. PubMed ID: 16807457
[TBL] [Abstract][Full Text] [Related]
3. Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Nair JS; Kancherla R; Seiter K; Traganos F; Tse-Dinh YC
Ann N Y Acad Sci; 2000; 922():326-9. PubMed ID: 11193914
[No Abstract] [Full Text] [Related]
4. Bromodomain and hedgehog pathway targets in small cell lung cancer.
Kaur G; Reinhart RA; Monks A; Evans D; Morris J; Polley E; Teicher BA
Cancer Lett; 2016 Feb; 371(2):225-39. PubMed ID: 26683772
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Rossman J; Reddy V; Cantor A; Miley D; Robert F
Lung Cancer; 2011 May; 72(2):219-23. PubMed ID: 20934233
[TBL] [Abstract][Full Text] [Related]
6. Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.
Saraiya B; Gounder M; Dutta J; Saleem A; Collazo C; Zimmerman L; Nazar A; Gharibo M; Schaar D; Lin Y; Shih W; Aisner J; Strair RK; Rubin EH
Anticancer Drugs; 2008 Apr; 19(4):411-20. PubMed ID: 18454051
[TBL] [Abstract][Full Text] [Related]
7. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.
Kancherla RR; Nair JS; Ahmed T; Durrani H; Seiter K; Mannancheril A; Tse-Dinh YC
Cancer; 2001 Feb; 91(3):463-71. PubMed ID: 11169927
[TBL] [Abstract][Full Text] [Related]
9. Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.
Kruczynski A; Barret JM; Van Hille B; Chansard N; Astruc J; Menon Y; Duchier C; Créancier L; Hill BT
Clin Cancer Res; 2004 May; 10(9):3156-68. PubMed ID: 15131057
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
[TBL] [Abstract][Full Text] [Related]
11. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
12. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
14. The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples.
Di Nicolantonio F; Knight LA; Whitehouse PA; Mercer SJ; Sharma S; Charlton PA; Norris D; Cree IA
Mol Cancer Ther; 2004 Dec; 3(12):1631-7. PubMed ID: 15634657
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Giaccone G; van Ark-Otte J; Scagliotti G; Capranico G; van der Valk P; Rubio G; Dalesio O; Lopez R; Zunino F; Walboomers J
Biochim Biophys Acta; 1995 Dec; 1264(3):337-46. PubMed ID: 8547322
[TBL] [Abstract][Full Text] [Related]
16. Potent antiviral activity of topoisomerase I and II inhibitors against Kaposi's sarcoma-associated herpesvirus.
González-Molleda L; Wang Y; Yuan Y
Antimicrob Agents Chemother; 2012 Feb; 56(2):893-902. PubMed ID: 22106228
[TBL] [Abstract][Full Text] [Related]
17. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
[TBL] [Abstract][Full Text] [Related]
18. Oligonucleotide-Recognizing Topoisomerase Inhibitors (OTIs): Precision Gene Editors for Neurodegenerative Diseases?
Bax BD; Sutormin D; McDonald NQ; Burley GA; Shelkovnikova T
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232843
[TBL] [Abstract][Full Text] [Related]
19. Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
Arivazhagan A; Kumar DM; Sagar V; Patric IR; Sridevi S; Thota B; Srividya MR; Prasanna K; Thennarasu K; Mondal N; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
J Neurooncol; 2012 Apr; 107(2):289-97. PubMed ID: 22102081
[TBL] [Abstract][Full Text] [Related]
20. Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases.
Singh S; Pandey VP; Yadav K; Yadav A; Dwivedi UN
Curr Protein Pept Sci; 2020; 21(11):1103-1142. PubMed ID: 32951576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]